1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Glecaprevir + pibrentasvir
Trade Name:
Maviret
Manufacturer/Distributor:
AbbVie Corporation
Classification:
Antiviral agent for treatment of chronic hepatitis C infection
ATC Class:
J05AP57 - glecaprevir and pibrentasvir
Status:
active
Notice of Compliance (yyyy/mm/dd):
2017/08/16
Date Marketed in Canada (yyyy/mm/dd):
2017/09/13
Presentation:
Tablet: 100 mg glecaprevir + 40 mg pibrentasvir. DIN: 02467550
Comments:
Maviret is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis.
Back to:
Drug Product Listings 
